Ando K, Saitoh A, Hino O, Takahashi R, Kimura M, Katsuki M
Department of DNA Biology, School of Medicine, Tokai University, Tokyo, Japan.
Cancer Res. 1992 Feb 15;52(4):978-82.
Forestomach papillomas and skin papillomas were induced very efficiently by a single dose administration of the chemical carcinogen methylnitrosourea (MNU) in transgenic mice (rasH2 line) carrying human hybrid c-Ha-ras genes, which encode the prototype p21 gene product. The incidence of forestomach papillomas was dose dependent; when 50 mg/kg of MNU were administered i.p., all of the transgenic mice (56 of 56) developed forestomach papillomas within 12 weeks after administration, whereas 5 and 0.5 mg/kg of MNU induced papillomas in 2 of 19 and 1 of 19 mice, respectively. Nine of 56 transgenic mice (16%) also developed skin papillomas at sites wounded by bites or scratches. Only 1 of 77 nontransgenic littermates developed forestomach papillomas after administration of 50 mg/kg of MNU, and no skin papillomas appeared within 12 weeks after MNU administration. The transgenes (integrated copy number, 5-6) in the tumors developed in 55 of 56 affected transgenic mice (98%) contained at least 1 copy of the transgene that was activated by somatic point mutation at the 12th codon, from GGC (Gly) to GAC (Asp). Because somatic point mutations at the 12th or 61st codon of transgenes have never been detected in normal tissues of transgenic mice thus far examined, these mutational activations of transgenes are tumor-specific events. RNA expression of these activated transgenes was also detected. From these results, it is suggested that somatic mutational activation of the human c-Ha-ras transgene plays a causative role in the occurrence of forestomach and skin papillomas induced by MNU administration in these transgenic mice. This transgenic mouse provides a unique screening system for chemicals that induce or suppress papillomagenesis.
在携带人类杂交c-Ha-ras基因(编码原型p21基因产物)的转基因小鼠(rasH2品系)中,通过单次给药化学致癌物甲基亚硝基脲(MNU)能非常高效地诱发前胃乳头瘤和皮肤乳头瘤。前胃乳头瘤的发生率呈剂量依赖性;当腹腔注射50mg/kg的MNU时,所有转基因小鼠(56只中的56只)在给药后12周内都出现了前胃乳头瘤,而5mg/kg和0.5mg/kg的MNU分别在19只小鼠中的2只和19只小鼠中的1只诱发了乳头瘤。56只转基因小鼠中有9只(16%)在被咬伤或抓伤的部位也出现了皮肤乳头瘤。77只非转基因同窝小鼠中只有1只在给予50mg/kg的MNU后出现了前胃乳头瘤,且在MNU给药后12周内未出现皮肤乳头瘤。56只受影响的转基因小鼠中有55只(98%)所患肿瘤中的转基因(整合拷贝数为5 - 6)至少有1个拷贝在第12密码子处发生了体细胞点突变,从GGC(甘氨酸)突变为GAC(天冬氨酸)。由于在迄今为止检测的转基因小鼠正常组织中从未检测到转基因第12或61密码子处的体细胞点突变,这些转基因的突变激活是肿瘤特异性事件。还检测到了这些激活转基因的RNA表达。从这些结果表明,人类c-Ha-ras转基因的体细胞突变激活在这些转基因小鼠中由MNU给药诱发的前胃和皮肤乳头瘤的发生中起致病作用。这种转基因小鼠为诱导或抑制乳头瘤发生的化学物质提供了一个独特的筛选系统。